126 related articles for article (PubMed ID: 30538383)
21. Assessment of therapeutic response of locally advanced breast cancer (LABC) patients undergoing neoadjuvant chemotherapy (NACT) monitored using sequential magnetic resonance spectroscopic imaging (MRSI).
Danishad KK; Sharma U; Sah RG; Seenu V; Parshad R; Jagannathan NR
NMR Biomed; 2010 Apr; 23(3):233-41. PubMed ID: 20175134
[TBL] [Abstract][Full Text] [Related]
22. Estimation of BCL-2 protein in carcinoma of the breast and its clinical correlation in locally advanced breast cancer.
Aggarwal H; Lubana PS; Jain DK; Mathur RK
J Cancer Res Ther; 2007; 3(4):207-10. PubMed ID: 18270395
[TBL] [Abstract][Full Text] [Related]
23. Feasibility of breast conservation surgery in locally advanced breast cancer downstaged by neoadjuvant chemotherapy: a study in mastectomy specimens using simulation lumpectomy.
Viswambharan JK; Kadambari D; Iyengar KR; Srinivasan K
Indian J Cancer; 2005; 42(1):30-4. PubMed ID: 15805689
[TBL] [Abstract][Full Text] [Related]
24. Pathological predictive factors for tumor response in locally advanced breast carcinomas treated with anthracyclin-based neoadjuvant chemotherapy.
Patel T; Gupta A; Shah M
J Cancer Res Ther; 2013; 9(2):245-9. PubMed ID: 23771367
[TBL] [Abstract][Full Text] [Related]
25. Influence of ABCB1 C3435T and C1236T gene polymorphisms on tumour response to docetaxel-based neo-adjuvant chemotherapy in locally advanced breast cancer patients of South India.
Priyadarshini R; Raj GM; Kayal S; Ramesh A; Shewade DG
J Clin Pharm Ther; 2019 Apr; 44(2):188-196. PubMed ID: 30637776
[TBL] [Abstract][Full Text] [Related]
26. Breast conservative surgery: is it appropriate for locally advanced breast cancer following downstaging by neoadjuvant chemotherapy? A pathological assessment.
Moneer M; El-Didi M; Khaled H
Breast; 1999 Dec; 8(6):315-9. PubMed ID: 14731459
[TBL] [Abstract][Full Text] [Related]
27. A Comparative Validation of Primary Surgical Versus Post-neo-adjuvant Chemotherapy Sentinel Lymph Node Biopsy for Stage III Breast Cancers.
Agarwal G; Rajan S; Gambhir S; Lal P; Krishnani N; Kheruka S
World J Surg; 2016 Jul; 40(7):1583-9. PubMed ID: 26324160
[TBL] [Abstract][Full Text] [Related]
28. Diffusion-weighted magnetic resonance imaging for pretreatment prediction and monitoring of treatment response of patients with locally advanced breast cancer undergoing neoadjuvant chemotherapy.
Nilsen L; Fangberget A; Geier O; Olsen DR; Seierstad T
Acta Oncol; 2010 Apr; 49(3):354-60. PubMed ID: 20397769
[TBL] [Abstract][Full Text] [Related]
29. Predictive value of MGMT, hMLH1, hMSH2 and BRCA1 protein expression for pathological complete response to neoadjuvant chemotherapy in basal-like breast cancer patients.
Nakai K; Mitomi H; Alkam Y; Arakawa A; Yao T; Tokuda E; Saito M; Kasumi F
Cancer Chemother Pharmacol; 2012 Apr; 69(4):923-30. PubMed ID: 22083523
[TBL] [Abstract][Full Text] [Related]
30. Can Multi-Parametric MR Based Approach Improve the Predictive Value of Pathological and Clinical Therapeutic Response in Breast Cancer Patients?
Sharma U; Agarwal K; Sah RG; Parshad R; Seenu V; Mathur S; Gupta SD; Jagannathan NR
Front Oncol; 2018; 8():319. PubMed ID: 30159254
[TBL] [Abstract][Full Text] [Related]
31. Molecular types and neoadjuvant chemotherapy in patients with breast cancer- while molecular shifting is more common in luminal a tumors, the pathologic complete response is most frequently observed in her-2 like tumors.
Salim DK; Mutlu H; Eryilmaz MK; Musri FY; Tural D; Gunduz S; Coskun HS
Asian Pac J Cancer Prev; 2014; 15(21):9379-83. PubMed ID: 25422228
[TBL] [Abstract][Full Text] [Related]
32. Efficacy of Neoadjuvant Endocrine Therapy Versus Neoadjuvant Chemotherapy in ER-positive Breast Cancer: Results From a Prospective Institutional Database.
LeVasseur N; Willemsma KA; Li H; Gondara L; Yip WC; Illmann C; Chia SK; Simmons C
Clin Breast Cancer; 2019 Dec; 19(6):e683-e689. PubMed ID: 31279611
[TBL] [Abstract][Full Text] [Related]
33. Clinical and pathologic response following taxane based neoadjuvant chemotherapy in locally advanced breast cancer patients in a tertiary care centre in India.
Sivasanker M; Sistla SC; Manwar SA; Vivekanandam S
Indian J Cancer; 2016; 53(2):220-225. PubMed ID: 28071613
[TBL] [Abstract][Full Text] [Related]
34. Longitudinal study of the assessment by MRI and diffusion-weighted imaging of tumor response in patients with locally advanced breast cancer undergoing neoadjuvant chemotherapy.
Sharma U; Danishad KK; Seenu V; Jagannathan NR
NMR Biomed; 2009 Jan; 22(1):104-13. PubMed ID: 18384182
[TBL] [Abstract][Full Text] [Related]
35. Taxane and anthracycline based neoadjuvant chemotherapy for locally advanced breast cancer: institutional experience.
Gogia A; Raina V; Deo SV; Shukla NK; Mohanti BK; Sharma DN
Asian Pac J Cancer Prev; 2014; 15(5):1989-92. PubMed ID: 24716923
[TBL] [Abstract][Full Text] [Related]
36. [Role of clustered HER2/neu amplification as a marker for a special sensitivity to neoadjuvant anti-HER2 therapy with trastuzumab in patients with stage II-III breast cancer].
Kolyadina IV; Zavalishina LE; Ganshina IP; Andreeva YY; Frank GA; Gordeeva OO; Zhukova LG; Meshcheryakov AA; Savelov NA; Tuzova EA; Morozov DA; Poddubnaya IV
Arkh Patol; 2019; 81(6):56-62. PubMed ID: 31851193
[TBL] [Abstract][Full Text] [Related]
37. Prospective Assessment of Systemic MicroRNAs as Markers of Response to Neoadjuvant Chemotherapy in Breast Cancer.
McGuire A; Casey MC; Waldron RM; Heneghan H; Kalinina O; Holian E; McDermott A; Lowery AJ; Newell J; Dwyer RM; Miller N; Keane M; Brown JAL; Kerin MJ
Cancers (Basel); 2020 Jul; 12(7):. PubMed ID: 32645898
[TBL] [Abstract][Full Text] [Related]
38. Summated chemotherapy dose-intensity versus loco-regional response in locally advanced breast cancer: its possible implications.
Datta NR; Rajkumar A; Basu R
Indian J Cancer; 2003; 40(4):127-34. PubMed ID: 14716108
[TBL] [Abstract][Full Text] [Related]
39. [Phase II clinical trial of neoadjuvant therapy with carboplatin plus paclitaxel for locally advanced triple-negative breast cancer].
Ma WY; Zhang P; Zhang BL; Wang X; Xu XZ; Zheng S; Wang JY; Cai RG; Yuan P; Ma F; Fan Y; Xu BH
Zhonghua Zhong Liu Za Zhi; 2012 Oct; 34(10):770-4. PubMed ID: 23291072
[TBL] [Abstract][Full Text] [Related]
40. Expression of ER, PgR, HER-2, and Ki-67 in core biopsies and in definitive histological specimens in patients with locally advanced breast cancer treated with neoadjuvant chemotherapy.
Rossi L; Verrico M; Tomao S; Ricci F; Fontana A; Spinelli GP; Colonna M; Vici P; Tomao F
Cancer Chemother Pharmacol; 2020 Jan; 85(1):105-111. PubMed ID: 31754747
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
